The Palpable Prostate

Prostate cancer topics, links and more. Now at 200+ posts!

News: Health Day, Medical News Today, ScienceDaily, Urol Times, Urotoday, Zero Cancer Papers: Pubmed (all), Pubmed (Free only), Amedeo
Journals: Eur Urol, J Urol, JCO, The Prostate Others Pubmed Central Journals (Free): Adv Urol, BMC Urol, J Endourol, Kor J Urol, Rev Urol, Ther Adv Urol, Urol Ann
Reviews: Cochrane Summaries, PC Infolink Newsletters: PCRI, US Too General Medical Reviews: f1000, Health News Review

Saturday, April 8, 2017

Finding freely available research articles

A new Firefox and Chrome browser extension creates a small button on the right side of the screen whenever you visit a journal article's web page. If it is green then it found the article freely and  legally available on a pre-print server or the article was not pay-walled in the first place.

To install the extension simply go the site using Firefox or Chrome and click on the large button.

Once it is installed any time you visit an article it will place the aforementioned button on the right side of the screen. If green click the button to get to an open access version of the article. If the button is grey then it was unable to find a free legal source.  The FAQ also refers to Gold and Blue buttons but none of the sites I visited had those.

This article discusses as well as some other similar sites for uncovering open access material:

Tuesday, January 3, 2017

Female physicians, saunas

Female vs. Male Physicians In a recent study that Harvard researchers published in JAMA, it was found that patients over 65 years old had lower death rates and lower hospital re-admission rates if they were treated by a female physician rather than a male doctor. The difference was small (11.07% vs 11.49% in adjusted 30-day mortality and 15.02% vs 15.57% in adjusted re-admissions) but if applied to the entire US population would represent a potential 32,000 fewer deaths. The study was done over the period January 1, 2011, to December 31, 2014 using a 20% random sample of all Medicare patients in this category. This represents over 1.5 million hospitalizations. Their results are consistent with a previous study [PMID: 8769910] that found that female doctors were more likely to provide preventative tests and counseling. See this [NPR article]. [PMID: 27992617] [Full Text].

Saunas A recent 20 year follow up study out of Finland found that men taking a sauna 4-7 times a week were 66% less likely to be diagnosed with dementia than those taking a sauna once a week. Not only was the effect very large but a dose response relationship was found increasing the likelihood that the effect is meaningful. (This is one of the Bradford Hill criteria for assessing studies). This follows a long list of other [claimed benefits] from saunas. See [Science Bulletin] [Abstract]

Friday, November 25, 2016

The Rule of 72 and PSA Doubling Time

A common approximation used in finance is that an investment which grows at x% per year will double in roughly 72/x years.  It is known as the rule of 72. What is of interest here is that it not only applies to finance but also PSA doubling time.

First consider the case of an investment.  Suppose an investment grows at 12% per year.  Then according to the aforementioned rule it will double in about
   72/12 = 6 years  (rule of 72 approximation)
This is close to the exact value (rounded to one decimal place) of
   1/log2(1+12/100) = 1/log2(1.12) = 6.1 years   (exact)
This can be double checked by entering that formula into the Google search bar.

(Here log2(x) represents the logarithm to the base 2 of x.  In the case that x is a power of 2 the value of log2(x) is the number of 2's to multiply together to get the argument.  For example, log2(8) = 3 because multiplying three twos gives 8, i.e. 2 * 2 * 2 = 8. If x is not a power of 2 then it will be between the log2 values of the nearby powers of 2. For example, log2(5)=2.321928 is between log2(4) = 2 and log2(8) = 3.)

We can use this rule to approximate PSA doubling time (PSADT).  Suppose the PSA is 0.100 at the beginning of the year and 0.112 at the end of the year.  Thus, it is increasing at .112 / .100 - 1 = .12 = 12% per year.   Using the rule of 72 this implies that the PSA will double in
   PSADT = 72/12 = 6 years   (rule of 72 approximation)
which, as before, is close to the exact value of
   PSADT = 1/log2(1+12/100) = 1/log2(1.12) = 6.1 years   (exact)
Although we used years above we can use any time period.  For example, suppose the PSA were growing at 2% per quarter.  Then it will double in
   PSADT = 72/2 = 36 quarters = 9 years   (rule of 72)
This is close to the exact number of
   PSADT = 1/log2(1+2/100) = 1/log2(1.02) = 35 quarters = 8.75 years   (exact)
There are some significant caveats.

1. The use of PSADT assumes constant exponential growth of the cancer cells.  That is, the percentage increase from period to period does not systematically change.  Such constant exponential growth would be the case if a plot of log2(PSA) vs. time were roughly linear.  If the entire plot were not roughly linear but sections of the plot were then each such section may have a different PSADT value.  For example, before and after a treatment intervention one might see different PSADT values.

2. The discussion above uses the Rule of 72 to approximate doubling time using only two PSA values but that is normally regarded as insufficient.  Typically PSADT should be calculated based on at least 3 PSA values to help eliminate the natural variation in PSA values.  Thus the above is only a first approximation before performing a more reliable calculation.

There is a more comprehensive discussion of PSADT calculations in this series of 4 blog posts:

Also, Wikipedia discusses the accuracy of the Rule of 72 on this page: [Wikipedia Rule of 72]

Tuesday, November 15, 2016

2016 AUA Meeting

[Updated: December 2, 2015] >br />
Highlights of the 2016 American Urology Association (AUA) meeting have recently been published.

Key topics relating to prostate cancer included:

- Molecular imaging. PSMA is expressed in prostate cancer and radiotracers can detect it.  The highlights include discussion of such imaging as well as the use of antibodies targeting PSMA to deliver toxic drugs directly to the cancer cells.

- Active Surveillance

- new prognostic markers aimed at distinguishing between disease having significant potential for malignancy vs. more benign disease

See the link above for the summary.

Another summary of some recent results can be found here: [PMID:27895809] [free full text]

Sunday, October 2, 2016

Blog updates for September 2016

Oct 2, 2016. In Grape Seed Extract we add: Although the 62% reduction in prostate cancer among the high grape seed extract group is eye opening there is only one clinical trial on grape seed extract and prostate cancer: [ - prostate cancer and grape seed extract]. In comparison there are 27 clinical trials on metformin and prostate cancer: [ - prostate cancer and metformin] so the bets seem to be much more on [metformin] at this point.

Friday, September 23, 2016

Grape Seed Extract

[Updated October 2, 2016]

This 2011 report on the VITAL study of 35,239 men found no effect on the development of prostate cancer for chondroitin, coenzyme Q10, fish oil, garlic, ginkgo biloba, ginseng, glucosamine or saw palmetto; however, it did find a 41% reduction in the development of prostate cancer among those who took grape seed oil supplements and a 62% reduction in the development of prostate cancer among those who took doses higher than those found in multivitamins over a 10 year period. Low doses of grape seed extract, primarily from multivitamins, did not show any reduction in prostate cancer development.

There were some limitations to the VITAL study and the authors did not recommend that taking such supplements but if any of the above substances work to reduce the likelihood of the development of prostate cancer then it would seem that grape seed oil supplements would be more likely than the others. Also, the study did not look at patients who already have prostate cancer but of course if it works in one set of people it might work in another. [PMID: 21598177] [full free text].

This 2014 study of grape seed extract found an anti-cancer effect against prostate cancer cells in test tubes. [PMID: 24191894] which adds to the evidence in the VITAL study.

Although the 62% reduction in prostate cancer among the high grape seed extract group is eye opening there is only one clinical trial on grape seed extract and prostate cancer: - prostate cancer and grape seed extract. In comparison there are 27 clinical trials on metformin and prostate cancer: - prostate cancer and metformin so the bets seem to be much more on metformin at this point. For more information on grape seed extract (side effects, etc.) see the pages at and Memorial Sloan Kettering. Additional discussion and references on grape seed extract can be found in a 2014 review of chemoprevention strategies [PMID: 24389535] [full free text] .

Monday, August 1, 2016

Blog updates for July 2016

July 22, 2016. In Metformin and Prostate Cancer we added statin references: Other recent work suggests benefit from combination therapy of metformin with statins [PMC3329836 full free text], [news release], p53 stabilizers [PMID: 26900800], chemotherapy [PMID: 27118574].